INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS)
Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections and Treatment Use Open-Label Extension Study
Sponsor: Cerus Corporation
This PHASE3 trial investigates Anemia and is currently ongoing. Cerus Corporation leads this study, which shows 16 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
16 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE3
-
Apr 2022 — Oct 2023 [monthly]
Recruiting PHASE3
▶ Show 11 earlier versions
-
May 2021 — Apr 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Feb 2020 — Aug 2020 [monthly]
Recruiting PHASE3
-
Aug 2019 — Feb 2020 [monthly]
Recruiting PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jun 2017 — Mar 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Jun 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cerus Corporation
For direct contact, visit the study record on ClinicalTrials.gov .